The effects of vaginal bromocriptine and dienogest on women with adenomyosis: a clinical study

Adenomyosis occurs when endometrial glands and stroma develop in the myometrium, leading to symptoms such as pelvic pain and heavy menstrual bleeding.

This randomized, double-blinded, controlled trial study was conducted on patients with adenomyosis referred to the Rasul-e-Akram Hospital. Group A received vaginal bromocriptine, and group B received dienogest. Transvaginal ultrasonography (TVS), visual analog scale (VAS), and pictorial blood loss assessment chart (PBLAC) evaluation were performed at the beginning and after 3, 6, and 9 months of the study.

The mean blood visual chart 3 and 6 months after intervention in the bromocriptine group was significantly lower than the dienogest group (P < 0.001). The mean intensity of menstrual pain 3 months after intervention was significantly lower in the dienogest group compared to the bromocriptine group (P < 0.001). There was a significant improvement in TVS appearance in both groups at the 6-month follow-up.

Dienogest and bromocriptine both effectively reduced pain intensity, menstrual bleeding, and sonographic characteristics in patients with adenomyosis.